Other
Non-deductible AIPR&D
Vertex Pharmaceuticals Non-deductible AIPR&D remained flat by 0.0% to 93.5% in Q4 2024 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2024Feb 13, 2026
How to read this metric
An increase indicates higher non-deductible acquisition costs, which can inflate the effective tax rate and reduce net income.
Detailed definition
This metric represents the impact of non-deductible acquired in-process research and development (AIPR&D) costs on the c...
Peer comparison
Common in biotech and pharma companies that frequently acquire smaller firms to bolster their R&D pipelines.
Metric ID:
other_effective_income_tax_rate_reconciliation_nondeduct_44267aHistorical Data
2 years
| FY'23 | FY'24 | |
|---|---|---|
| Value | 0% | 373.8% |
Range0% – 373.8%
Non-deductible AIPR&D at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's non-deductible aipr&d?
- Vertex Pharmaceuticals (VRTX) reported non-deductible aipr&d of 93.5% in Q4 2024.
- What does non-deductible aipr&d mean?
- The tax impact of research and development costs from acquisitions that cannot be deducted from taxable income.